Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, Ranjana H Advani, Babis Andreadis, Nancy L Bartlett, L Elizabeth Budde, Paolo F Caimi, Julie E Chang, Beth Christian, Sven DeVos, Bhagirathbhai Dholaria, Luis E Fayad, Thomas M Habermann, Muhammad Saad Hamid, Francisco Hernandez-Ilizaliturri, Boyu Hu, Mark S Kaminski, Yasmin Karimi, Christopher R Kelsey, Rebecca King, Susan Krivacic, Ann S LaCasce, Megan Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B Roberts, Hayder Saeed, Stephen D Smith, Jakub Svoboda, Lode J Swinnen, Joseph Tuscano, Julie M Vose, Mary A Dwyer, Hema Sundar
Novel targeted therapies (small molecule inhibitors, antibody-drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton's tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL...
November 2023: Journal of the National Comprehensive Cancer Network: JNCCN